| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b064f6e833a2caebe48bb48a50d9be9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 |
| filingDate |
2017-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f53ecd13289222aa80a274d0511e690
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a39e24e7f8fb3b129e091c8dafeec37c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_519df176b4ddb8e6c7f601e6c84ec18f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79b8abf5bb797d3da9a39e17c760ddd8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f27eb04f5f8fe372d96900147d8a0d6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e378580431ef3f5c2a675111a29a3c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e231039d53e033afc6741b8ffd54a9b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c05ef84b36b0fdab6e5658208f204ff9 |
| publicationDate |
2018-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018015558-A1 |
| titleOfInvention |
Imidazolyl-substituted indole derivatives binding 5-ht7 serotonin receptor and pharmaceutical compositions thereof |
| abstract |
The invention relates to a new class of substituted indole derivatives that are able to activate 5-HT 7 serotonin receptor. These compounds bind 5-HT 7 serotonin receptor with high affinity and selectivity, while possessing favourable physicochemical properties. The compounds of the invention are the first described low-basicity 5-HT 7 receptor agonists. The invention also relates to use of such compounds in the treatment or prevention of 5-HT 7 receptor-related disorders, especially of the central nervous system. The invention also relates to the isotopically labelled compounds for use in the in vivo diagnostics or imaging of a 5-HT 7 serotonin receptor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112174937-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019136558-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11572354-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112174937-B |
| priorityDate |
2016-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |